The American Medical Association has issued a formal call for Congress to establish federal safeguards governing the development and deployment of AI-powered mental health chatbots. The AMA’s position outlines concerns about consumer safety, data privacy, and the lack of clinical oversight in many commercially available products.
The organization is specifically asking for transparency requirements around how these tools are trained, what their limitations are, and how users are informed about the distinction between AI support and professional clinical care.
The call comes amid rapid growth in the consumer mental health app market, which has expanded significantly as AI capabilities have improved.
The AMA’s position reflects a broader shift in how medical and regulatory bodies are beginning to think about AI in mental health. The emphasis on transparency and clinical oversight aligns with how responsible tools in this space should operate.
For clinicians, this signals that the field is moving toward greater accountability — which is ultimately good for patients and for the profession. Products that are designed with clinical collaboration in mind are better positioned to meet these standards.
Therapists who are already thinking about how AI fits into their practice are ahead of this curve. The regulatory environment will likely reward tools that keep clinicians informed and in control.